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Chlamydia pneumoniae is a worldwide respiratory pathogen involved in 620% of community-acquired pneumonias 
and in about 5% of acute exacerbations of chronic bronchitis. Preliminary data also indicate a possible association 
between Chlamydia pneumoniae infection and asthma. Further studies are needed to elucidate whether Chlamydia 
pneumoniae is merely a precipitant of asthma symptoms or is actually one of the causes of asthma. 
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Chlamydia pneumoniae has recently been recognized as 
a cause of respiratory tract infections [1,2]. It has been 
classified as a thud species of the Chlamydia genus by 
means of ultrastructural and DNA homology analysis 
C. pneumoniae is an obligate intracellular, Gram- 
negative bacterium involved in a wide spectrum of 
respiratory tract mfections of the upper respiratory tract 
(pharyngitis, sinusitis and otitis) and lower respira- 
tory tract (acute bronchitis, exacerbation of chronic 
bronchitis and asthma, and community-acquired 
pneumonias) in both immunocompetent and immuno- 
compromised subjects [4-211. Several studies have 
recently stressed the importance of this agent in the 
development of respiratory diseases, showing a high 
incidence and prevalence of infections worldwide. 
Specific antibody prevalence in Western countries is 
low in pre-school children and climbs to over 50% in 
adults, remaining high in old age due to C. pneumoniae 
reinfection among adults [7]. 
In t h i s  paper the clinical characteristics of C. 
pneumoniae acute infection will be discussed, focusing 
on the possible pathogenetic role of t h i s  agent in 
asthma. 
[31. 
DISEASES ASSOCIATED WITH ACUTE 
C. PNEUMONIA€ INFECTION 
C. pneumoniae seems to be an important cause of 
human respiratory tract disease. Several reports show a 
high incidence of infection in community-acquired 
pneumonia, ranging &om 6% to 25%, and a remarkable 
role in pneumonia outbreaks in closed communities 
like military garrisons, schools and f d e s  [8,12-161. 
Further, C. pneumoniae is involved in upper respiratory 
tract infections (pharyngitis, sinusitis, otitis), acute 
bronchitis and exacerbations of chronic bronchtis 
[5,6]. Recently, Hahn et al [lo] reported a possible 
etiopathogenetic role of t h i s  pathogen in adult onset of 
asthma and in asthma exacerbation. 
Several other diseases associated with C. pneumoniae 
infection, such as erythema nodosum, Guillain-Barrk 
syndrome, culture-negative endocarditis, thyroiditis, 
arthritis and encephalitis, have been sporadically 
reported [22,24]. Seroepidemiologic evidence of a 
possible association between C. pneumoniae infection 
and sarcoidosis has also been suggested [25]. Saikku et 
al [26,27] and other authors [28-321 also found an 
association between C. pneumoniae and coronary artery 
disease. Table 1 summarizes published data on the 
incidence of C. pneumoniae infections. 
Table 1 Incidence of Chlamydia pneumoniae infections 
Disease Range of incidence 
Asymptomatic infection Common 
Flu-like syndrome Common 
Community-acquired pneumonia 6-25% 
Outbreaks in closed communities - 
Family outbreaks - 
Upper respiratory tract infections 510% 
COPD exacerbations 4 5 %  
Asthma attacks 1-18% 
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UPPER RESPIRATORY TRACT INFECTION 
C. pneumoniae is involved in the etiology of acute 
pharyngitis, otitis and sinusitis with an incidence 
ranging from 5% to 10% [32,33]. In these diseases, no 
specific clinical h e s t a t i o n s  have been shown. How- 
ever, acute pharyngitis could be relatively severe with 
hoarseness, and one-third of patients present exudates 
with or without fever. Upper respiratory tract mfec- 
tions often herald or are associated with infections of 
the lower respiratory tract. 
LOWER RESPIRATORY TRACT INFECTION (LRTI) 
C. pneumoniae is increasingly reported as an important 
etiologic agent of LRTI. About 5% of COPD exacer- 
bations are sustained by C. pneumoniae. Possible chronic 
C. pneumoniae infection in chronic bronchitis was 
suggested by Blasi et al [6], who found a sigdicantly 
higher frequency of IgG anti-Chlamydia pneumoniae 
antibody, exceeding 63%, in patients with exacer- 
bations of COPD compared to controls. Ths remark- 
ably h g h  prevalence could be due to either chronic 
infection by C. pneumoniae, as suggested by the increase 
of specific IgG prevalence and geometric mean titer 
with age, or a higher rate of acute infection in such 
patients. Von Hertzen et al [34] found no Merences in 
serum IgG antibodies between patients and controls, 
but the difference in serum IgA prevalence was 
sigdicant. Moreover, local sputum IgA antibodies 
against C. pneumoniae, absent in the majority of 
pneumonia patients, were a common finding in the 
sputa of chronic bronchitis patients, along with local 
antibodies against Haemophifus infuenzae and Branhamella 
cutarrhafis. C. pneumoniae might therefore be added to 
these bacteria, which have invariably been associated 
with the pathogenesis of chronic bronchitis. 
Most reports rank t h i s  agent as being among the 
three most common etiologic agents of community- 
acquired pneumonia, generally presenting a mild, and 
in some cases self-limiting, clinical course [35,36], 
although sporadic cases of severe pneumonia have been 
reported [36,37]. The radiographic pattern of pneu- 
monia is extremely variable, with a reported high 
incidence of sub-segmental consolidation [38,39]. 
Kleemola et al reported a seroepidemiologic study 
showing pneumonia epidemics in military garrisons 
sustained by C. pneumoniae, each epidemic lasting more 
than 6 months with an infective rate of about 80 per 
1000 [S]. 
F d y  transmission, child to child, was described 
in Japan in 1990 [13]. Mordhorst et al [14] described 
an outbreak of C. pneumoniae infections in four farm 
families living close together in Denmark, with an 
unusually high incidence of symptomatic infections, 
particularly lower respiratory tract infections, among 
family members. These data support the human-to- 
human contact spread of C. pneumoniae infection, and 
point to the role of this agent in f d y  cluster 
respiratory infections, although Aldous et al [15], in 
a serologic study of family serum samples conducted 
in 1966-1969, reported that acute infections more 
often af€ected a single family member than multiple 
members. 
Blasi et al recorded a high rate (75%) of infection 
in two family outbreaks [16]. These data are in contrast 
to the low incidence of infection recorded during 
epidemics in military trainees in Finland [8] and in the 
serologic study of Aldous et al [15], while they are 
consistent with those reported by Mordhorst et al [14], 
who observed a family cluster with relatively high rate 
of infection. 
In contrast to the numerous epidemiologic studies 
carried out in the general population, only limited data 
on C. pneumoniae infection in immunocompromised 
subjects are present in the literature [17-211. Blasi et al 
have recently published preliminary results on C. 
pneumoniae seroprevalence in HIV-1-infected intra- 
venous drug users and HIV-1 vertically infected 
children [17]. The seroprevalence of C. pneumoniae in 
the HIV-1-infected intravenous drug users (IDUs) was 
si&icantly higher than in both HIV-1-negative IDUs 
and immunocompetent subjects matched for age and 
sex. Recent reports suggest a possible role of C. 
pneumoniae as an etiologic agent of pneumonia in HIV- 
1-positive subjects [18-21]. In a retrospective serologic 
study, Blasi et al [21] observed an outbreak of C. 
pneumoniae infection in an ex-injection drug user 
community, where almost 25% of the residents were 
HIV-1 positive. The epidemic occurred in a small 
group of 26 subjects living and working in the same 
place. Their rate of HN-1 positivity was remarkably 
hgh  (50%). A higher C. pneumoniae infection rate in 
HIV-1 -positive subjects was observed, with more than 
76% of HIV-1-positive patients compared to only 38% 
of HIV-negative subjects suffering from acute C. 
pneumoniae mfections. Moreover, most pneumonias 
occurred in HIV-1-positive patients. All lung infections 
were mild to moderate in severity, with a spontaneous 
recovery in one HIV-1-negative subject. 
ASTHMA 
Hyperresponsiveness is a key factor in the pathogenesis 
of asthma that might be determined by genetic factors 
and/or environmental exposures. Atopy, air pollution 
and smoke seem to be strongly associated with 
bronchial hyperresponsiveness. Moreover, familial 
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predisposition and/or genetic transmission of bronchal 
hyperresponsiveness have recently been observed 
[40,41]. in  children, the role of viral infection in acute 
exacerbations of asthma has long been recognized, 
although its role in the pathogenesis of asthma is still 
controversial [42]. Less is known about the association 
between infections and asthma in adults. Commonly, 
influenza and the common cold precede asthma attacks, 
suggesting an etiopathogenic link between viral 
infection and acute exacerbation. This has been 
inferred tlom several epidemiologic studies, mainly 
conducted in the pediatric population [43,44]. 
The role of viruses as precipitants of asthma 
symptoms in adults seems to be less relevant than in 
children but epidemiologic data are con0icting. Beasley 
et al [45] reported an etiologic role of viruses in 10% 
of acute exacerbations of asthma, with a higher 
incidence (36%) in severe attacks. However, Sokhandan 
et al[46] did not find any evidence of viral infection in 
a s m a l l  group of patients with acute asthma exacer- 
bations. More recently, Nicholson et al 2471 reported 
that 89% of patients with a cold had asthma symptoms. 
Moreover, the authors found that 44% of episodes 
with reductions in mean peak expiratory flow rate 
150  l/min were associated with laboratory-confirmed 
infections, rhinoviruses and coronaviruses being pre- 
dominant. 
Bacterial infection seems to play a minor role in 
asthma attacks [48], although some evidence has drawn 
attention to Mycoplasma pneumoniae and recently to 
C. pnarmoniae [10,49]. The latter plays an important 
aetiopathogenetic role in the development of acute 
respiratory tract infections [2,6] and Hahn et al [lo] 
reported a possible association of C. pneumoniae 
infection with wheezing and adult-onset asthma. The 
results of t h i s  study showed a dose-response relationship 
between specific antibody titer level and prevalence of 
wheeze. Moreover, four out of 19 patients with acute 
C. pneumoniae infection subsequently developed asthma, 
and four others had exacerbation of previously diag- 
nosed asthma. 
AUegra et al [ll] showed that acute exacerbation 
of asthma was associated with dect ion in 20% of their 
patients. Interestingly, viruses were involved in about 
9% of asthma attacks, while acute infection with 
intracellular bacteria was detected in 11% of cases. Most 
of the latter (7/8 cases) were due to C. pneumoniae 
infection. Emre et al[50] reported the association of C. 
pneumoniae infection and reactive airway disease in 
children. The authors indicated that C. pneumoniae was 
a trigger of wheezing in a s h t i c  children and that 
treatment with macrolides, which are active against this 
agent, may improve the course of reactive airway 
disease in these patients. 
Other findings also seem to indicate C. pneumoniae 
infection as a possible explanation for an increase of 
asthma in recent years [Sl]. For instance, cross-sectional 
data indicate an age-specific seroprevalence pattern [52] 
similar to the prevalence pattern of adult asthma [53], 
C. pneumoniae infection preceding symptomatic adult 
asthma by about 10 years. Seroepidemiologic data h m  
Flnland [54] also show an increasing seroprevalence rate 
associated with increased asthma prevalence. Hahn and 
Golubjatnikov [55] reported a study on patients with 
adult-onset asthma in which 100% .of patients were C. 
pneumoniae seroreactive. 
C. pneumoniae has also been cultured from adult 
patients with acute exacerbation of asthma [56,57]. 
Moreover, Emre et al [50] identified the agent by 
culture in children with symptomatic asthma. In 
another study, Cunningham et al [58] showed that C. 
pneumoniae could be detected by polymerase chain 
reaction in a large proportion (47%) of children with 
asthma, both during exacerbations (24%) and when 
asymptomatic (27.7%). The latter study seems to 
support the hypothesis of a possible C. pneumoniae 
chronic infection in subjects with asthma. 
Hahn has recently defined a ‘Chlamydia-asthma’ 
hypothesis [59]. The hypothesis is based on the 
following evidence. 
1. Production of C. pneumoniae-specific IgE and 
cytokines, along with a direct lesion of epithelial cells 
by the agent, leadmg to inhibition of ciliary motion 
[60] and a possible shedding of cells with an enhanced 
penetration of aeroallergens. 
2. The capacity of Chlamydia, during reinfection 
or chronic infection, to produce T-cell-mediated im- 
munopathologic diseases, with the possibility that C. 
pneurnoniae could act as a long-term asthma promoter. 
3. C. pneumoniae could infect vascular smooth 
muscle 1611 and promote bronchial hyperreactivity via 
bronchial muscle infection. 
Hence, the data available to date seem to support 
an etiologic link between C. pneumoniae infection and 
asthma, in both adults and children. 
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